Patient-specific dose finding in phase I clinical trials

DOI10.1080/02664763.2018.1428735OpenAlexW2790732631MaRDI QIDQ5036370

M.D. Moniruzzaman Moni, M. Iftakhar Alam

Publication date: 23 February 2022

Published in: Journal of Applied Statistics (Search for Journal in Brave)

Full work available at URL: https://doi.org/10.1080/02664763.2018.1428735

zbMATH Keywords

maximum tolerated dosedose-response modeldose finding studiespatients' heterogeneityphase i trial

Mathematics Subject Classification ID

Applications of statistics (62Pxx)

Cites Work

• Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
• Optimal Bayesian-feasible dose escalation for cancer phase I trials
• Continual Reassessment Method for Ordered Groups
• Patient‐Specific Dose Finding Based on Bivariate Outcomes and Covariates
• TWO-SAMPLE CONTINUAL REASSESSMENT METHOD
• Dose-Response Models with Covariates

This page was built for publication: Patient-specific dose finding in phase I clinical trials